Last $28.04 USD
Change Today +0.03 / 0.11%
Volume 676.2K
SPNC On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SPNC) Snapshot

Open
$28.11
Previous Close
$28.01
Day High
$28.17
Day Low
$27.65
52 Week High
03/21/14 - $31.94
52 Week Low
09/23/13 - $15.76
Market Cap
1.2B
Average Volume 10 Days
413.9K
EPS TTM
$-0.18
Shares Outstanding
41.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRANETICS CORP (SPNC)

Related News

No related news articles were found.

spectranetics corp (SPNC) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SPNC) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; and coronary atherectomy and thrombectomy, which are aspiration and cardiac laser catheters for the treatment of blockages in the heart. Its primary vascular intervention products include the Turbo Elite and Turbo-Tandem laser catheters and the TAPAS drug delivery catheters for peripheral atherectomy; crossing catheters, such as the Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, GlideLight, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

575 Employees
Last Reported Date: 09/5/14
Founded in 1984

spectranetics corp (SPNC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $596.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $316.2K
Chief Operating Officer
Total Annual Compensation: $265.6K
Senior Vice President of Lead Management Sale...
Total Annual Compensation: $265.7K
Senior Vice President and General Counsel
Total Annual Compensation: $238.9K
Compensation as of Fiscal Year 2013.

spectranetics corp (SPNC) Key Developments

The Spectranetics Corporation Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014

The Spectranetics Corporation Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014 . Venue: Delamar Hotel, Greenwich, Connecticut, United States.

The Spectranetics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 11:30 AM

The Spectranetics Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 11:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Scott William Drake, Chief Executive Officer, President and Director.

The Spectranetics Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014

The Spectranetics Corporation reported unaudited consolidated earnings results for the second quarter six months ended June 30, 2014. For the quarter, revenue was $43,555,000 against $39,453,000 a year ago. Operating loss was $5,829,000 against $678,000 a year ago. Loss before taxes was $6,319,000 against $664,000 a year ago. Net loss was $6,565,000 or $0.16 per basic and diluted share against $728,000 or $0.02 per basic and diluted share a year ago. Non-GAAP net loss was $2,431,000 or $0.06 per share against $280,000 or $0.01 per share a year ago. LBITDA was $3,221,000 against EBITDA of $1,945,000 a year ago. Adjusted EBITDA was $777,000 against $2,147,000 a year ago. The decrease was planned and primarily resulted the sales force expansion. Cash flow used in operating activities was $1,111,000 against cash flow generated by operating activities of $2,048,000 a year ago. For the six months, revenue was $83,169,000 against $77,128,000 a year ago. Operating loss was $11,347,000 against $2,183,000 a year ago. Loss before taxes was $11,833,000 against $2,198,000 a year ago. Net loss was $12,226,000 or $0.29 per basic and diluted share against $1,687,000 or $0.05 per basic and diluted share a year ago. Non-GAAP net loss was $7,646,000 or $0.18 per share against $873,000 or $0.02 per share a year ago. LBITDA was $6,140,000 against EBITDA of $3,033,000 a year ago. Adjusted LBITDA was $1,833,000 against adjusted EBITDA of $3,437,000 a year ago. The company projects revenue for 2014 to be in the range of $198.5 million to $201.0 million, an increase of 25% to 27% over 2013. This includes a projected $27.0 million contribution from the recently acquired AngioScore products. Excluding the AngioScore revenue, organic revenue is anticipated to be in the range of $171.5 to $174.0 million, or 8% to 10% growth over 2013, which is consistent with previous outlook. The organic revenue includes a modest contribution from the recently approved ISR indication and mechanical tools, offset by anticipated and inherent disruption associated with the integration of the AngioScore sales team. Net loss for 2014 is projected to be in the range of $36.0 million to $38.0 million, or $0.85 to $0.90 per share. Non-GAAP net loss for 2014 is projected to be in the range of $13.3 to $15.3 million, or $0.32 to $0.36 per share. Adjusted EBITDA is anticipated to be in the range of $0.0 to $2.0 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPNC:US $28.04 USD +0.03

SPNC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ABIOMED Inc $25.35 USD -0.08
Cardiovascular Systems Inc $26.86 USD -0.13
CryoLife Inc $10.21 USD +0.07
Endologix Inc $14.04 USD -0.42
Vascular Solutions Inc $23.46 USD -0.22
View Industry Companies
 

Industry Analysis

SPNC

Industry Average

Valuation SPNC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit www.spectranetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.